Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
$ 18.695 0.245 (1.33%) Market Cap: 21.04 Bil Enterprise Value: 37.42 Bil PE Ratio: 0 PB Ratio: 3.30 GF Score: 59/100

Q3 2020 Teva Pharmaceutical Industries Ltd Earnings Call Transcript

Nov 05, 2020 / 01:00PM GMT
Release Date Price: $8.61 (-6.51%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Teva Pharmaceutical Third Quarter 2020 Earnings Call. (Operator Instructions) I must advise you that this conference is being recorded today.

And I would now like to hand the conference over to your first speaker, Kevin Mannix, Senior Vice President, Investor Relations. Please go ahead, sir.

Kevin C. Mannix
Teva Pharmaceutical Industries Limited - SVP of IR

Thank you, Valerie, and thank you, everyone, for joining us today to discuss Teva's third quarter 2020 financial results. On the call with me are KÃ¥re Schultz, Teva's Chief Executive Officer; Eli Kalif, Chief Financial Officer; and Brendan O'Grady, Teva's Head of North America Commercial. We hope you've had an opportunity to review our earnings press release, which was issued earlier this morning. A copy of the release as well as a copy of the slides being presented on this call can be found on our website at www.tevapharm.com as well as through our Teva Investor

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot